BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24021463)

  • 1. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Giannetti AM; Zheng X; Skelton NJ; Wang W; Bravo BJ; Bair KW; Baumeister T; Cheng E; Crocker L; Feng Y; Gunzner-Toste J; Ho YC; Hua R; Liederer BM; Liu Y; Ma X; O'Brien T; Oeh J; Sampath D; Shen Y; Wang C; Wang L; Wu H; Xiao Y; Yuen PW; Zak M; Zhao G; Zhao Q; Dragovich PS
    J Med Chem; 2014 Feb; 57(3):770-92. PubMed ID: 24405419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Bair KW; Baumeister T; Ho YC; Liederer BM; Liu X; Liu Y; O'Brien T; Oeh J; Sampath D; Skelton N; Wang L; Wang W; Wu H; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4875-85. PubMed ID: 23899614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
    Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
    Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
    Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
    Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.
    Zak M; Liederer BM; Sampath D; Yuen PW; Bair KW; Baumeister T; Buckmelter AJ; Clodfelter KH; Cheng E; Crocker L; Fu B; Han B; Li G; Ho YC; Lin J; Liu X; Ly J; O'Brien T; Reynolds DJ; Skelton N; Smith CC; Tay S; Wang W; Wang Z; Xiao Y; Zhang L; Zhao G; Zheng X; Dragovich PS
    Bioorg Med Chem Lett; 2015 Feb; 25(3):529-41. PubMed ID: 25556090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
    Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Gunzner-Toste J; Liederer BM; Ly J; O'Brien T; Oh A; Wang L; Wang W; Xiao Y; Zak M; Zhao G; Yuen PW; Bair KW
    J Med Chem; 2013 Aug; 56(16):6413-33. PubMed ID: 23859118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.
    Palacios DS; Meredith E; Kawanami T; Adams C; Chen X; Darsigny V; Geno E; Palermo M; Baird D; Boynton G; Busby SA; George EL; Guy C; Hewett J; Tierney L; Thigale S; Weihofen W; Wang L; White N; Yin M; Argikar UA
    Bioorg Med Chem Lett; 2018 Feb; 28(3):365-370. PubMed ID: 29275937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
    Chen W; Dong G; He S; Xu T; Wang X; Liu N; Zhang W; Miao C; Sheng C
    Bioorg Med Chem Lett; 2016 Feb; 26(3):765-768. PubMed ID: 26755394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
    Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
    Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
    J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Gunzner-Toste J; Zhao G; Yuen PW; Bair KW
    J Med Chem; 2013 Jun; 56(12):4921-37. PubMed ID: 23617784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
    Christensen MK; Erichsen KD; Olesen UH; Tjørnelund J; Fristrup P; Thougaard A; Nielsen SJ; Sehested M; Jensen PB; Loza E; Kalvinsh I; Garten A; Kiess W; Björkling F
    J Med Chem; 2013 Nov; 56(22):9071-88. PubMed ID: 24164086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
    Zak M; Yuen PW; Liu X; Patel S; Sampath D; Oeh J; Liederer BM; Wang W; O'Brien T; Xiao Y; Skelton N; Hua R; Sodhi J; Wang Y; Zhang L; Zhao G; Zheng X; Ho YC; Bair KW; Dragovich PS
    J Med Chem; 2016 Sep; 59(18):8345-68. PubMed ID: 27541271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.
    Gunzner-Toste J; Zhao G; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Fu B; Han B; Ho YC; Kley N; Liang X; Liederer BM; Lin J; Mukadam S; O'Brien T; Oh A; Reynolds DJ; Sharma G; Skelton N; Smith CC; Sodhi J; Wang W; Wang Z; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X; Bair KW; Dragovich PS
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3531-8. PubMed ID: 23668988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
    Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
    Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
    Clark DE; Waszkowycz B; Wong M; Lockey PM; Adalbert R; Gilley J; Clark J; Coleman MP
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2920-2926. PubMed ID: 27158141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.